Business Wire

VBI Vaccines Announces Phase 2a Clinical Evaluation of VBI-1901 Cancer Vaccine Candidate in Combination with GSK’s AS01B Adjuvant System in Recurrent Glioblastoma Patients

Share

VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced a collaboration with GlaxoSmithKline (GSK) to clinically evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, with GSK’s proprietary AS01B adjuvant system. As part of the collaboration, VBI plans to add an additional study arm to Part B of the company’s ongoing, multi-center, open-label Phase 1/2a clinical study targeting recurrent glioblastoma (GBM), a cytomegalovirus (CMV)-associated tumor.

“VBI-1901 has shown encouraging results in Part A of the ongoing Phase 1/2a clinical study in recurrent GBM patients and we are excited to be able to expand the scope of Part B to assess the candidate in combination with AS01B, a highly-innovative adjuvant system that has contributed to positive results in combination with the gE antigen in GSK’s shingles vaccine, Shingrix,” said David E. Anderson, Ph.D., VBI’s Chief Scientific Officer. “VBI’s enveloped virus-like particle (eVLP) technology, the basis for VBI-1901, is highly versatile and has demonstrated clinical potency in both preventative and therapeutic settings. We believe that these two technologies may be an ideal match for next-generation vaccines, and we look forward to seeing the results of this collaboration.”

“This is the first time we have partnered with a biopharma company to evaluate AS01B in such a clinical setting and the first time this adjuvant will be assessed in oncology for GBM patients. We have shown the ability of AS01B to boost T-cell mediated immunity and believe the combination of AS01B and VBI-1901 could have benefits for patients with glioblastoma, a rare but devastating cancer,” said Emmanuel Hanon, Senior Vice President, Head of R&D at GSK Vaccines.

In Part A of the study, VBI-1901 adjuvanted with granulocyte-macrophage colony-stimulating factor (GM-CSF) was well-tolerated at all doses. Further, three out of six patients in the high-dose (10 µg) cohort demonstrated evidence of stable disease by magnetic resonance imaging (MRI), which correlated with vaccine-induced immune response. Based on this safety and immunogenicity data, the high-dose was identified as the optimal therapeutic dose to test in the Part B extension phase of the study.

Part B of the ongoing Phase 1/2a clinical study is now planned to be a two-arm, open-label study, enrolling 20 first-recurrent GBM patients to receive VBI-1901 in combination with either GM-CSF or AS01B as immunomodulatory adjuvants. Enrollment of the 10 patients in the VBI-1901 with GM-CSF arm was initiated at the end of July 2019. Initiation of enrollment of the 10 patients in the VBI-1901 with AS01B arm is expected later in the second half of 2019, subject to U.S. Food and Drug Administration (FDA) acceptance of the amended protocol.

VBI’s ongoing two-part study is being conducted at The Neurological Institute of New York Columbia University Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital.

About the Phase 1/2a Study Design

VBI’s two-part Phase 1/2a study is a multi-center, open-label, dose-escalation study of VBI-1901 in up to 38 patients with recurrent GBM:

  • Part A:
    • Dose-escalation phase that defined the safety, tolerability, and optimal dose level of VBI-1901 in recurrent GBM patients, with any number of prior recurrences
    • This phase enrolled 18 recurrent GBM patients across three dose cohorts of VBI-1901: 0.4 µg, 2.0 µg, and 10.0 µg
    • Enrollment completed in December 2018
  • Part B:
    • Subsequent extension of the optimal dose level, 10.0 µg, as defined in the Part A dose escalation phase
    • This phase will be a two-arm study, enrolling 10 patients in each arm, assessing VBI-1901 in combination with either GM-CSF or AS01B as immunomodulatory adjuvants
    • Part B will enroll first-recurrent GBM patients only

VBI-1901 is administered intradermally when adjuvanted with granulocyte-macrophage colony-stimulating factor (GM-CSF), and will be administered intramuscularly when adjuvanted with GSK's proprietary AS01B adjuvant system. Patients in both phases of the study will receive the vaccine immunotherapeutic every four weeks until clinical progression.

Additional information, including a detailed description of the study design, eligibility criteria, and investigator sites, is available at ClinicalTrials.gov using identifier NCT03382977.

About Glioblastoma (GBM)

Scientific literature suggests cytomegalovirus (CMV) infection is prevalent in multiple solid tumors, including GBM, gliomas, and breast cancer, among others. GBM is among the most common and aggressive malignant primary brain tumors. In the U.S. alone, 12,000 new cases are diagnosed each year. The current standard of care for treating GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and is exceptionally lethal.

About VBI Vaccines Inc.

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only commercially-approved trivalent hepatitis B vaccine, Sci-B-Vac®, which is approved for use in Israel and 10 other countries and is currently in a Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s eVLP Platform technology allows for the development of enveloped virus-like particle (eVLP) vaccines that closely mimic the target virus to elicit a potent immune response. Integrating its cytomegalovirus (CMV) expertise with the eVLP platform technology, VBI’s lead eVLP program candidates include a prophylactic CMV vaccine candidate and a glioblastoma (GBM) vaccine immunotherapeutic candidate. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

Website Home: http://www.vbivaccines.com/

News and Insights: http://www.vbivaccines.com/wire/

Investors: http://www.vbivaccines.com/investors/

About GlaxoSmithKline (GSK) and AS01 Adjuvant System

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon® adjuvant licensed from Antigenics LLC, a wholly owned subsidiary of Agenus Inc. (NASDAQ: AGEN), MPL and liposomes. For further information please visit www.gsk.com/about-us/.

Cautionary Statement on Forward-looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The company cautions that such statements involve risks and uncertainties that may materially affect the company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the company's products. A discussion of these and other factors, including risks and uncertainties with respect to the company, is set forth in the Company's filings with the Securities and Exchange Commission and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 25, 2019, and filed with the Canadian security authorities at sedar.com on February 25, 2019, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

Contact information

VBI Contact
Nicole Anderson
Associate, Corporate Communications
Phone: (617) 830-3031 x124
Email: info@vbivaccines.com

VBI Investor Contact
Nell Beattie
Chief Business Officer
Email: ir@vbivaccines.com

VBI Media Contact
Burns McClellan, Inc.
Robert Flamm, Ph.D.
Phone: (212) 213-0006
Email: rflamm@burnsmc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Arthur D. Little Report Reveals Global CEOs’ First Learnings From COVID-19 Pandemic6.4.2020 12:13:00 EESTPress release

Global management consultancy Arthur D. Little (ADL) today released first learnings from global CEOs in the telecoms, transport and utility industries who delivered critical infrastructure services in Asia and Italy during the early spread of COVID-19. The Leading businesses through the COVID-19 crisis: First learnings from Hong Kong, Italy and Singapore Report is available free to help businesses facing the worst of COVID-19 deliver vital goods and services safely. The report urges companies to put people before short-term profits, avoid step-by-step measures, delegate authorities, intensify employee communications efforts, and work closely with governments, authorities and communities. “We can learn from one another, build resilience in our economy, and emerge from this crisis ready to innovate and restore,” said Ignacio García Alves, Chairman and CEO of Arthur D. Little. “This report gives CEOs unique peer-to-peer insight from leaders who maintained effective operations through the

flatex AG: Best Quarter Ever - Volatility Brings Absolute Record Growth6.4.2020 10:05:00 EESTPress release

The outstanding development since the beginning of the year at flatex AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) and DEGIRO continues on a sustained basis. flatex and DEGIRO gained more than 170,000 new customers on a pro forma basis in Q1 2020. 35,000 new customers (+218% compared to Q1/2019) opted for flatex and more than 135,000 customers opted for DEGIRO (+385% compared to Q1/2019). In the first quarter, flatex Bank processed 6.5 million securities transactions (+123% compared to Q1/2019), DEGIRO processed 10.8 million securities transactions (+134% compared to Q1/2019). The total number of transactions on a pro forma basis increased by almost 130% compared to the same quarter last year (pro forma Q1/2019: 7.5 million transactions) to 17.3 million. "The first quarter was a very exceptional one, each month was a record month. The current volatility in the markets is extremely good for our business, despite the reason for the volatility being anything but nice. However, lik

World Parkinson’s Day 2020: BIAL launches new campaign ‘Don’t let Parkinson’s stop you. Keep on moving’6.4.2020 10:02:00 EESTPress release

BIAL Pharmaceuticals has created a new film for World Parkinson’s Day 2020 to dispel the stigma around Parkinson’s and show the amazing achievements, breadth and diversity of people living with the condition. The film, “Keep on moving”, is the latest part of a worldwide campaign, launched by BIAL four years ago. The campaign aims to increase awareness and knowledge of Parkinson's Disease and to inspire and empower millions of people living with Parkinson’s around the world. Parkinson’s is a neurodegenerative disease that affects as many as 1.2 million people in Europe alone.1 As the disease progresses, everyday tasks such as bathing, dressing, eating, sleeping and even walking can become real challenges.2 The film aims to show that, despite this, Parkinson’s doesn’t need to define a person. It features consecutive sets of people doing what they love, whether it be playing the guitar, drumming, drawing or cooking. One person in each set has Parkinson’s and one does not. The focus is on

IDEMIA Ranked #1 in International NIST Benchmark for Iris Recognition6.4.2020 10:00:00 EESTPress release

IDEMIA’s algorithms have been awarded the top rank amongst all studied companies in the IREX 10: Identification Track of the NIST benchmark assessing iris recognition performance for identification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200406005250/en/ (Photo: Business Wire) IDEMIA, the global leader in Augmented Identity, confirms its leadership position on the biometric identification market by proving the best one eye accuracy in iris recognition. Iris identification systems allows us to search users against a database of enrolled credentials and return their proper identities when matched. Jean-Christophe Fondeur, CTO of IDEMIA, stated: “The results of IREX 10 confirm IDEMIA's leadership in biometric research since the early 1980s, and the expertise of IDEMIA's teams in this field. Ranking first in iris recognition once more shows how advanced our technology is. We are proud to have been among the main contribu

FOSSID and BearingPoint Enter Strategic Partnership Around Open Source Software Governance6.4.2020 10:00:00 EESTPress release

FOSSID, a leader in open source software compliance and security, and BearingPoint, a leader in open source management services, today announced their strategic partnership around free and open source software governance. After successfully cooperating in selected projects for more than two years, BearingPoint decided to choose FOSSID as its strategic provider of open source analysis tools. FOSSID’s technology provides high performance and accuracy in the code analysis services performed by BearingPoint. Whenever companies need to embrace free and open source software for speed of innovation, standardization, or quality, BearingPoint Business Services is there to efficiently help reduce risk and improve productivity. “Partnering with FOSSID helps us provide more value to our customers with higher speed and better accuracy,” says Donald Wachs, Head of BearingPoint Business Services. “Using FOSSID technology, we typically see more precise results with less redundancy, and we can speed up

SPIE Photonics Europe Digital Forum Set to Launch With Over 700 Presentations6.4.2020 09:00:00 EESTPress release

SPIE, the international society for optics and photonics, will be holding its inaugural Digital Forum during the week of 6-10 April. SPIE Photonics Europe 2020, which was set to run in Strasbourg, France, from 29 March to 2 April, will now be held completely online via a virtual and interactive format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200405005011/en/ SPIE, the international society for optics and photonics, will be holding its inaugural Digital Forum during the week of 6-10 April. (Graphic: Business Wire) The SPIE digital forum platform was developed in response to the inability to hold in-person conferences due to the global spread of COVID-19. The forums ensure the timely continuation of information exchange and discussion opportunities that the Society’s optics and photonics community values and relies on to advance research, product development, and collaborations. SPIE Photonics Europe Digital Forum, an e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom